Cited by 205Coenzyme Q10 studies and effectsParkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Randomized, Double-blind, Placebo-Controlled Trial on Symptomatic Effects of Coenzyme Q10 in Parkinson Disease

Storch, Alexander·2007·Archives of Neurology

DOI 10.1001/archneur.64.7.nct60005

Open this paper in CoChat — free account

Abstract

BACKGROUND: Major hallmarks in the pathophysiology of Parkinson disease are cellular energy depletion and oxidative stress leading to cellular dysfunction and death. Coenzyme Q(10) (CoQ(10)) is an electron acceptor bridging mitochondrial complexes I and II/III and a potent antioxidant that consistently partially recovers the function of dopaminergic neurons. OBJECTIVE: To determine whether nanoparticular CoQ(10) is safe and displays symptomatic effects in patients with midstage Parkinson disease without motor fluctuations. DESIGN: Multicenter, randomized, double-blind, placebo-controlled, stratified, parallel-group, single-dose trial. SETTING: Academic and nonacademic movement disorder clinics. PATIENTS: One hundred thirty-one patients with Parkinson disease without motor fluctuations and a stable antiparkinsonian treatment. Intervention Random assignment to placebo or nanoparticular CoQ(10) (100 mg 3 times a day) for a treatment period of 3 months. Stratification criterion was levodopa treatment. MAIN OUTCOME MEASURE: The subjects underwent evaluation with the Unified Parkinson's Disease Rating Scale (UPDRS) at each visit on a monthly basis. The primary outcome variable was the change of the sum score of the UPDRS parts II and III between the baseline and 3-month visits. RESULTS: One hundred thirty-one subjects were randomized according to the protocol. The mean changes of the sum UPDRS parts II/III score were -3.69 for the placebo group and -3.33 for the CoQ(10) group (P = .82). Statistical analysis according to the stratification did not result in significant changes of the primary outcome variable. No secondary outcome measure showed a significant change between the placebo group and the CoQ(10) group. The frequency and quality of adverse events were similar in both treatment groups. CONCLUSIONS: Nanoparticular CoQ(10) at a dosage of 300 mg/d is safe and well tolerated and leads to plasma levels similar to 1200 mg/d of standard formulations. Add-on CoQ(10) does not display symptomatic effects in midstage Parkinson disease.

Integrity signals

Registry

Crossref · 10.1001/archneur.64.7.nct60005

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Unified Parkinson's Disease Rating Scale
(2012) · Springer eBooks · doi:10.1007/springerreference_184495 · Cited by 3,071
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Parkinson's Disease
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,072
The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score
JENKINSON, C., FITZPATRICK, R., PETO, V., GREENHALL, R., & HYMAN, N. (1997) · Age and Ageing · doi:10.1093/ageing/26.5.353 · Cited by 1,321
Biochemical, physiological and medical aspects of ubiquinone function
Ernster, L., & Dallner, G. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(95)00028-3 · Cited by 1,246
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease
Schapira, A. H. V., Mann, V. M., Cooper, J. A. D., Dexter, D. T., Daniel, S. E., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb05809.x · Cited by 673
Coenzyme Q is an obligatory cofactor for uncoupling protein function
Echtay, K. S., Winkler, E., & Klingenberg, M. (2000) · Nature · doi:10.1038/35046114 · Cited by 334

Flagged first, then by citations

Show all 29 references

Sorted by citations

Items 101–200 of 204

Coenzyme Q10 supplementation in acute ischemic stroke: Is it beneficial in short-term administration?
Ramezani, M., Sahraei, Z., Simani, L., Heydari, K., & Shahidi, F. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2018.1541269 · Cited by 37
Coenzyme Q10 for Parkinson's disease
Liu, J., Wang, L., Zhan, S.-Y., & Xia, Y. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008150.pub2 · Cited by 36
Retracted
Potential Influences of Complementary Therapy on Motor and Non-Motor Complications in Parkinsonʼs Disease
Zesiewicz, T., & Evatt, M. L. (2009) · CNS Drugs · doi:10.2165/11310860-000000000-00000 · Cited by 35
Hydralazine Protects Nigrostriatal Dopaminergic Neurons From MPP+ and MPTP Induced Neurotoxicity: Roles of Nrf2-ARE Signaling Pathway
Guo, X., Han, C., Ma, K., Xia, Y. F., Wan, F. J., Yin, S., Kou, L., Sun, Y., Wu, J., Hu, J., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00271 · Cited by 33
Current Management of the Cognitive Dysfunction in Parkinson’s Disease: How Far Have We Come?
Vale, S. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-mr-193 · Cited by 33
Coenzyme Q10 for Parkinson's disease
Liu, J., Wang, L., Zhan, S.-Y., & Xia, Y. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008150.pub3 · Cited by 32
Retracted
Managing the patient with newly diagnosed Parkinson disease
Fernandez, H. H., Gálvez-Jiménez, N., & Singer, C. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79.s2a.01 · Cited by 31
Coenzyme Q10 and neuropsychiatric and neurological disorders: relevance for schizophrenia
Maguire, Á., Hargreaves, A., & Gill, M. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2018.1556481 · Cited by 30
Nutrition and Lifestyle Interventions for Managing Parkinson’s Disease: A Narrative Review
Lister, T. (2020) · Journal of Movement Disorders · doi:10.14802/jmd.20006 · Cited by 33
Novel therapeutic strategies in Parkinson’s disease
Klivènyi, P., & Vécsei, L. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0742-4 · Cited by 28
Current Experience in Testing Mitochondrial Nutrients in Disorders Featuring Oxidative Stress and Mitochondrial Dysfunction: Rational Design of Chemoprevention Trials
Pagano, G., Talamanca, A. A., Castello, G., Cordero, M. D., d’Ischia, M., Gadaleta, M. N., Pallardó, F. V., Petrović, S. Ž., Tiano, L., & Zatterale, A. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151120169 · Cited by 26
“A set of studies was focused on 16 clinical trials (of which 10 controlled trials) testing CoQ10 supplementation in 1185 patients with eight neurologic disorders [65,152–166].”
Background
Aging-Related Disorders and Mitochondrial Dysfunction: A Critical Review for Prospect Mitoprotective Strategies Based on Mitochondrial Nutrient Mixtures
Pagano, G., Pallardó, F. V., Lyakhovich, A., Tiano, L., Fittipaldi, M. R., Toscanesi, M., & Trifuoggi, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197060 · Cited by 27
Early pharmacologic treatment in Parkinson's disease.
Hauser, R. A. (2010) · PubMed · Cited by 27
Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases
Ebrahimi, A., Kamyab, A., Hosseini, S., Ebrahimi, S., & Ashkani‐Esfahani, S. (2023) · Biochemistry Research International · doi:10.1155/2023/5510874 · Cited by 29
“Biochemistry Research International However, new studies, including a phase III clinical trial, showed controversial pieces of evidence regarding the benefcial efects of CoQ10 for the treatment of PD [73, 74].”
Background
Coenzyme Q10 and Parkinsonian Syndromes: A Systematic Review
Jiménez‐Jiménez, F. J., Alonso‐Navarro, H., García‐Martín, E., & Agúndez, J. A. G. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060975 · Cited by 24
“Storch et al., 2007 [33] One hundred thirty-one patients with PD without motor fluctuations and a stable antiparkinsonian treatment.”
Background
Considerations Regarding the Etiology and Future Treatment of Autosomal Recessive Versus Idiopathic Parkinson Disease
Kitada, T., Tomlinson, J. J., Ao, H. S., Grimes, D. A., & Schlossmacher, M. G. (2012) · Current Treatment Options in Neurology · doi:10.1007/s11940-012-0175-8 · Cited by 23
Organoselenotriazoles attenuate oxidative damage induced by mitochondrial dysfunction in mev-1 Caenorhabditis elegans mutants
Soares, A. T. G., Rodrigues, L. B. L., Salgueiro, W. G., Forno, A. H. D., Rodrigues, C. D. F., Sacramento, M., Franco, J. L., Alves, D. A. C., Oliveira, R. D. P., Pinton, S., et al. (2019) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2019.01.017 · Cited by 23
Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction
Orsucci, D., Filosto, M., Siciliano, G., & Mancuso, M. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.2009.00221.x · Cited by 23
Mitochondria: Prospective Targets for Neuroprotection in Parkinson’s Disease
Yadav, A., Agarwal, S., Tiwari, S. K., & Chaturvedi, R. K. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140305224545 · Cited by 22
Statins and the risk of Parkinson disease: an update on the controversy
Becker, C., & Meier, C. R. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902859956 · Cited by 21
“Several studies have shown beneficial effects of orally administered Co Q10 to patients with PD, as high doses of Co Q10 seem to delay disease progression [54-58].”
Background
Nutraceuticals as Modulators of Autophagy: Relevance in Parkinson’s Disease
Rakowski, M., Lekki-Porębski, S. A., & Grzelak, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073625 · Cited by 20
Molecular pathways and genetic aspects of Parkinson’s disease: from bench to bedside
Napoli, M. D., Shah, I. M., & Stewart, D. A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.12.1693 · Cited by 19
Targeting Mitochondria for Neuroprotection in Parkinson Disease
Schapira, A. H. V., & Patel, S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.64 · Cited by 20
Comparison of chocolate to cacao-free white chocolate in Parkinson’s disease: a single-dose, investigator-blinded, placebo-controlled, crossover trial
Wolz, M., Schleiffer, C., Klingelhöfer, L., Schneider, C. B., Proft, F., Schwanebeck, U., Reichmann, H., Riederer, P. F., & Storch, A. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6527-1 · Cited by 19
Self-citation
Neuronutrition: An Emerging Concept
Topçuoğlu, M. A., & Arsava, E. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-53171-7_10 · Cited by 19
Nutraceutical Strategies for Targeting Mitochondrial Dysfunction in Neurodegenerative Diseases
Davì, F., Iaconis, A., Cordaro, M., Paola, R. D., & Fusco, R. (2025) · Foods · doi:10.3390/foods14132193 · Cited by 20
“However, more recent investigations, including a Phase III clinical trial, have yielded controversial evidence regarding the beneficial effects of CoQ10 for PD treatment [239,240].”
Mitochondria research and neurodegenerative diseases: On the track to understanding the biological world of high complexity
Mendes, D., Peixoto, F., Oliveira, M. M., Andrade, P. B., & Videira, R. A. (2022) · Mitochondrion · doi:10.1016/j.mito.2022.05.001 · Cited by 18
New small molecules for the treatment of Parkinson's disease
Müller, T. H. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.504711 · Cited by 17
“I Delayed start TEMPO [20,67,68] + II Delayed start ADAGIO [22] + III Delayed start PROUD [23] IV Placebo-controlled Coenzyme Q10 [69,70] V Placebo-controlled TCH 346 [71] VI Placebo-controlled Riluzol [72] Interval to LD LD-sparing VII Placebo-controlled DATATOP [17] + VIII Placebo-controlled SINDEPAR [73] + IX Place…”
Method
Effects of dietary supplements, foods, and dietary patterns in Parkinson’s disease: meta-analysis and systematic review of randomized and crossover studies
Wu, L., Chu, L., Pang, Y., Huo, J., Cao, H., Tian, Q., & Gao, Q. (2024) · European Journal of Clinical Nutrition · doi:10.1038/s41430-024-01411-1 · Cited by 16
“Two studies were excluded for lack of outcome data after the intervention [16, 17].”
DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson’s disease
Müller, T. H. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2263357 · Cited by 14
“Many failures of the past already exist, i.e. coenzyme Q 10 [44–46].”
Background
Investigating the individual and combined effects of coenzyme Q10 and vitamin C on CLP-induced cardiac injury in rats
Üstündağ, H., Demir, Ö., Huyut, M. T., & Yüce, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-52932-5 · Cited by 14
“In this study, a polymicrobial sepsis model was generated utilizing the widely accepted CLP method 29 .”
Method
Serum lipid levels are associated with the prevalence but not with the disease progression of multiple system atrophy in a Chinese population
Cao, B., Guo, X., Chen, K. G., Song, W., Huang, R., Wei, Q., Zhao, B., & Shang, H. (2013) · Neurological Research · doi:10.1179/1743132813y.0000000277 · Cited by 14
What’s in the pipeline for the treatment of Parkinson’s disease?
Sommer, D. B., & Stacy, M. A. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.12.1829 · Cited by 14
Neuroprotection in Parkinson's Disease: A Systematic Review of the Preclinical Data
Douna, H., Bavelaar, B. M., Pellikaan, H., Olivier, B., & Pieters, T. (2012) · The Open Pharmacology Journal · doi:10.2174/1874143601206010012 · Cited by 13
Lithium carbonate and coenzyme Q10 reduce cell death in a cell model of Machado-Joseph disease
Lopes‐Ramos, C. M., Pereira, T. C., Dogini, D. B., Gilioli, R., & Lopes‐Cendes, Í. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165805 · Cited by 13
“Besides being a natural compound, safe and well tolerated with few side effects (30,40), CoQ10 is able to cross the brain barrier, as demonstrated in animal studies.”
Background
Neuroprotection in Parkinson's Disease
Schapira, A. H. V. (2009) · Blue books of neurology · doi:10.1016/b978-1-4160-6641-5.00018-0 · Cited by 14
Koenzym Q10 beim Morbus Parkinson
Storch, A. (2007) · Der Nervenarzt · doi:10.1007/s00115-007-2285-1 · Cited by 13
Self-citation
Mapping the Research of Ferroptosis in Parkinson’s Disease from 2013 to 2023: A Scientometric Review
Chen, Y., Wu, Z., Li, S., Chen, Q., Wang, L., Qi, X., Tian, C., & Yang, M. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s458026 · Cited by 12
Effects of coenzyme Q10 supplementation on oxidative stress and antioxidant enzyme activity in glazers with occupational cadmium exposure: A randomized, double-blind, placebo-controlled crossover clinical trial
Hormozi, M., Mirzaei, R., Nakhaee, A., Payandeh, A., Izadi, S., & Haghighi, J. D. (2018) · Toxicology and Industrial Health · doi:10.1177/0748233718809256 · Cited by 12
“Although some of the hematology safety data were not measured during the coenzyme Q10 administration, multiple studies (Baggio et al., 1994; Feigin et al., 1996; Ferrante et al., 2005; Ikematsu et al., 2006; Rosenfeldt et al., 2007; Shults et al., 2004; Storch et al., 2007; Young et al., 2012) have reported that coenz…”
Background
A Diet for Dopaminergic Neurons?
Giovanni, G. D. (2009) · Springer eBooks · doi:10.1007/978-3-211-92660-4_27 · Cited by 12
Existing and emerging mitochondrial-targeting therapies for altering Parkinson's disease severity and progression
Pienaar, I. S., & Chinnery, P. F. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.010 · Cited by 11
“Storch et al. (2007) aimed to determine in amulticenter, randomized, double-blind, placebo-controlled, stratified, parallel-group, single-dose trial, whether nanoparticular CoQ10 is safe and displays symptomatic effects in 131 patients with midstage PD without motor fluctuations.”
Background
The Impact of Coenzyme Q10 on Neurodegeneration: a Comprehensive Review
Kadian, M., Sharma, G., Pandita, S., Sharma, K., Shrivasatava, K., Saini, N., & Kumar, A. (2022) · Current Pharmacology Reports · doi:10.1007/s40495-021-00273-6 · Cited by 11
Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinsons Disease?
Kirches, E. (2009) · Current Genomics · doi:10.2174/138920209789503879 · Cited by 11
Stimulation of electron transport as potential novel therapy in Parkinson's disease with mitochondrial dysfunction
Vos, M. H., Verstreken, P., & Klein, C. (2015) · Biochemical Society Transactions · doi:10.1042/bst20140325 · Cited by 10
Drug Development for Rare Mitochondrial Disorders
Hurko, O. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0179-4 · Cited by 10
A comprehensive review of natural compounds and their structure–activity relationship in Parkinson’s disease: exploring potential mechanisms
Merghany, R. M., El-Sawi, S. A., Naser, A. F. A., Ezzat, S. M., Moustafa, S. F., & Meselhy, M. R. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03462-4 · Cited by 8
“…effects of Coenzyme Q10 (CoQ10) in patients with PD were investigated in several eligible clinical studies (Strijks et al. 1997; Shults et al. 2002; Müller et al. 2003; Investigators 2007; Storch et al. 2007; Beal et al. 2014; Jie 2014; Wang et al. 2014; Li et al. 2015; Yoritaka et al. 2015).”
The effect of diet on Parkinson’s disease progression, symptoms and severity: a review of randomised controlled trials
Prasad, A., Glover, C., Shuler, M. G. H., Dayal, V., & Lithander, F. E. (2025) · Proceedings of The Nutrition Society · doi:10.1017/s0029665125101213 · Cited by 8
Acetyl-L-Carnitine in Parkinson’s Disease
Stefania, M., Rovito, N., Carocci, A., & Genchi, G. (2012) · InTech eBooks · doi:10.5772/19668 · Cited by 8
“Nevertheless, coenzyme Q10 protects primary dopaminergic neurons in vitro against cell death induced by MPTP (Gille et al., 2004), and seems that at least partially restores the function of complex I in the tissues of patients with PD (Shults et al., 1998; Storch et al., 2007).”
Background
Epidemiologic Risk and Prevention and Interventions in Parkinson Disease: From a Nutrition-Based Perspective
Zhang, F., Liu, Y., Zhu, Y., Yu, Q.-Y., Msigwa, S. S., Zeng, Z.-H., Zhang, X., Wu, H.-M., & Zhu, J. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.01.028 · Cited by 7
Dietary intake of coenzyme Q10 reduces oxidative stress in patients with acute ischemic stroke: a double-blind, randomized placebo-controlled study
Mojaver, A., Khazaei, M., Ahmadpanah, M., Zarei, M., Asl, S. S., Habibi, P., & Shahidi, ‬. (2025) · Neurological Research · doi:10.1080/01616412.2025.2470712 · Cited by 6
“Various clinical and animal studies, have shown the beneficial effects of CoQ10 on oxidative stress and inflammation [5,10,28,33–36].”
Preparing for Parkinson’s disease prevention trials: Current progress and future directions
Bouhadoun, S., Delva, A., Schwarzschild, M. A., & Postuma, R. B. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251334050 · Cited by 6
Mechanistic insights into ubiquinone Q10 in Parkinson’s disease: mitochondrial protection, ferroptosis inhibition, and antioxidant recycling
Saadh, M. J., Saeed, T. N., Al-Hussainy, A. F., Kyada, A., Ballal, S., Kundlas, M., Sabarivani, A., Rizaev, J. A., Taher, S. G., Alwan, M., et al. (2025) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2025.2541698 · Cited by 6
Nutraceuticals in brain health
Haldar, S., Ghosh, S., Kumar, V., Saini, S., Debrupa Lahiri, A., & Roy, P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820593-8.00029-x · Cited by 5
Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment
Greenlee, H., Crew, K. D., Maurer, M., Kalinsky, K. M., Cremers, S., Naini, A., Tsai, W. Y., Shi, Z., Brogan, F., & Hershman, D. L. (2025) · Integrative Cancer Therapies · doi:10.1177/15347354251388014 · Cited by 4
Dietary supplements for Parkinson's disease: State of the science
Prasad, A., Shuler, M. G. H., Flanagan, R., Dayal, V., & Lithander, F. E. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261446386 · Cited by 4
“While two other RCTs 51,52 could not replicate these ﬁ ndings and reported no between-group differences in UPDRS total score, the latter trial by Storch and colleagues 52 did ﬁ nd statistically signi ﬁ cant between-group improvements in H&Y scores.”
Clinical Benefits of Therapeutic Interventions Targeting Mitochondria in Parkinson’s Disease Patients
Ciocca, M., & Pizzamiglio, C. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230330122444 · Cited by 4
“No significant improvement in the UPDRS-III scores was noted [26].”
Background
Parkinson’s Disease and Aging
Andersen, J. K., & Chinta, S. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-23246-1_8 · Cited by 4
Dietary Supplements: Current Knowledge and Future Frontiers
Costello, R. B., Leser, M., & Coates, P. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-385-5_28 · Cited by 4
Parkinson’s Disease: An Overview of Etiology, Clinical Manifestations, and Treatment
Dalvi, A., Lyons, K. E., & Pahwa, R. (2014) · Springer eBooks · doi:10.1007/978-3-319-08046-8_1 · Cited by 4
Antioxidant and neuroprotective effects of ubiquinol diacetate: Insights from SH-SY5Y cell line and Caenorhabditis elegans models of Parkinson's disease
Micucci, M., Battistelli, M., Burattini, S., Osman, R., Onesimo, F., Mari, M., Retini, M., Versari, I., Pagliarani, B., Tarozzi, A., et al. (2026) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2026.105023 · Cited by 3
Therapeutic roles of coenzyme Q10 in peripheral nerve injury-induced neurosensory disturbances: Mechanistic insights from injury to recovery
Vachirarojpisan, T., Srivichit, B., Vaseenon, S., Powcharoen, W., & Imerb, N. (2024) · Nutrition Research · doi:10.1016/j.nutres.2024.07.011 · Cited by 5
Neuroprotective strategies in Parkinson’s disease
Garg, D., & Desai, S. (2021) · Annals of Movement Disorders · doi:10.4103/aomd.aomd_38_21 · Cited by 3
Electron Transport Chain
Aerts, L., & Morais, V. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803783-6.00002-x · Cited by 3
Medical treatment of the motor features of Parkinson disease
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C. L., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00006-8 · Cited by 3
Low protein diet: Its relevance to Manganese-induced neurotoxicity in rats treated with Coenzyme Q10 and/or Epigallocatechin-3-gallate.
Aboutaleb, A. S., Ahmed, H. I., Kamal, M. M., & Ali, A. A. (2021) · Azhar International Journal of Pharmaceutical and Medical Sciences/Azhar International Journal of Pharmaceutical and Medical Sciences · doi:10.21608/aijpms.2021.62632.1048 · Cited by 3
What Do Randomized Controlled Trials Inform Us About Potential Disease-Modifying Strategies for Parkinson’s Disease?
Ong, W., Leow, D. M.-K., Herr, D. R., & Yeo, C. J.-J. (2022) · NeuroMolecular Medicine · doi:10.1007/s12017-022-08718-x · Cited by 3
Novel Molecular Therapeutics in Parkinson's Disease
Gonçalves, S. A., Miranda, H. V., & Outeiro, T. F. (2012) · doi:10.1002/9781119967309.ch11 · Cited by 3
“However, trials using these types of molecules, such as coenzyme Q10, did not ameliorate PD symptoms (Storch et al., 2007).”
Background
Mitochondrial Function and Neurodegenerative Diseases
Wilkins, H. M., Weidling, I., Koppel, S., Wang, X., von Schulze, A., & Swerdlow, R. H. (2018) · The Molecular and Cellular Basis of Neurodegenerative Diseases · doi:10.1016/b978-0-12-811304-2.00013-4 · Cited by 2
Coenzyme Q10 as an adjunctive treatment for substance use disorders: a preclinical review
Adabi, R., Masoudi, A., Rafaiee, R., & Mohseni, F. (2025) · Journal of Addictive Diseases · doi:10.1080/10550887.2025.2521561 · Cited by 2
Integrating Herbs and Supplements in Managed Care: A Pharmacy Perspective
Elder, C. R., Mossbrucker, P., Davino-Ramaya, C. M., Bez, I., Lin, M. M., Terry, T. A., Thomas, E. A., & Jones, S. (2008) · The Permanente Journal · doi:10.7812/tpp/07-146 · Cited by 2
6Chapter Micronutrients for the Prevention of Diabetes and Improvement of the Standard Therapy
Prasad, K. N. (2010) · CRC Press eBooks · doi:10.1201/ebk1439821060-11 · Cited by 1
Parkinson’s Disease: Possible Mechanisms for Nutritional Approaches
Cherpak-Castagna, C. E., & Lare, S. J. V. (2020) · Journal of Restorative Medicine · doi:10.14200/jrm.2020.0104 · Cited by 1
Role of dietary antioxidants and redox status in Parkinson's disease
Amani, R., & Mehrabani, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89834-8.00048-9 · Cited by 1
Parkinson’s disease: will therapy move beyond dopaminergic medication?
Dézsi, L., & Vécsei, L. (2011) · Clinical Investigation · doi:10.4155/cli.11.12 · Cited by 1
Dietary Supplements in Older Adults
Dwyer, J. T., Costello, R. B., Merkel, J. M., & Coates, P. M. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1929-1_23 · Cited by 1
Micronutrients for the Prevention and Improvement of the Standard Therapy for Parkinson’s Disease
Prasad, K. N. (2019) · CRC Press eBooks · doi:10.1201/9780429243462-10 · Cited by 1
Pharmacologic Management of Parkinson Disease: Choice of Initial Therapy in Early Disease
Chen, J. J., & Pahwa, R. (2008) · Journal of Pharmacy Practice · doi:10.1177/0897190008318129 · Cited by 1
“However, the results have not been supported by subsequent randomized studies.(56,57)”
Result
CNS Drug Targets in Development and Future Perspectives
Kelly, J. P. (2009) · Wiley eBooks · doi:10.1002/9780470682920.ch9
Regulation der zellulären Plastizität in der adulten Substantia nigra: Effekte von reizreicher Umgebung und physischer Aktivität
Siebert, E. (2008) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-15548
Dietary Factors in Geriatric Neurology
Gu, Y., & Scarmeas, N. (2014) · Wiley eBooks · doi:10.1002/9781118730676.ch27
Natural Health Products in Parkinson Disease
Sadowski, C. A., & Heschuk, S. (2010) · Health care and disease management · doi:10.1002/9783527629480.ch6
Common mtDNA Polymorphisms and Neurodegenerative Disorders
Elson, J. L., & Samuels, D. C. (2011) · Springer eBooks · doi:10.1007/978-0-85729-701-3_4
“This is in part because antioxidant treatments have failed to benefi t patients in clinical trials [ 62 ] .”
Background
KOENCIM Q10 – KLINIČNA RABA
Pavlin, R. (2008) · Slovenian Medical Journal
Overview of Parkinson's Disease: Examing the role for the Gut-Brain-Gut axis and the use of Nutrients based on preclinical and clinical evidence
Koopman, H. J. M. (2013) · Utrecht University Repository (Utrecht University)
Effect of Ubiquinone and Resveratrol on Experimentally Induced
Kabel, P., & Kholy, S. S. E. (2013)
KATERE SO PRILAGODITVENE REAKCIJE NA TELESNO
Eiken, O. (2008)
Koenzym Q10 beim Morbus Parkinson : Symptomatische oder neuroprotektive Effekte?
Storch, A. (2007) · Der Nervenarzt
Self-citation
The Neuroprotective Role of Micronutrients in Parkinson’s Disease
Malkus, K. A., Tsika, E., & Ischiropoulos, H. (2009) · doi:10.1201/9781420073522-7
Role of Mitochondria in Parkinson’s Disease and Huntington’s Disease
Schapira, A. H. V. (2012) · Oxidative stress and disease · doi:10.1201/b12308-23
Simultaneous Activation of Nrf2 and Elevation of Dietary and Endogenous Antioxidants for Prevention and Improved Management of Parkinson’s Disease
Prasad, K. N. (2016) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-319-33486-8_15
Medical Treatment of Parkinson’s Disease
Valadas, A., & Ferreira, J. J. (2017) · Springer eBooks · doi:10.1007/978-3-7091-1628-9_14
Biological and Behavioural Markers of Parkinson’s Disease
Alamri, Y. (2017) · Otago University Research Archive (University of Otago)
Coenzyme Q10 deficiency in elderly: Can nutritional supplementation play a role? Mini review
Am, C., Teresa, M., Pumpo, M. D., Giovanni, M., & Benvenuto, A. (2018) · The European Research Journal · doi:10.18621/eurj.411682 · Cited by 1
“Some studies [55, 56, 61, 62] have shown beneficial effect s of oral CoQ10 supplementation in Parkinson's patients, while in other studies [63, 64] CoQ10 showed no evidence of clinical benefit.”
Result
Influence of Dietary Constituents on Motor and Non-motor Symptoms in Parkinson’s Disease
Löhle, M., & Reichmann, H. (2014) · Neuropsychiatric symptoms of neurological disease · doi:10.1007/978-3-319-09537-0_5
Medical treatment of Parkinson disease
Fahn, S., Jankovic, J. J., & Hallett, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-2369-4.00006-8
The Efficacy and Safety of Coenzyme Q10 in Preventing the Progression of Early Parkinson’s Disease: A Meta-Analysis
Roxas, R. C. D., & Jamora, R. D. G. (2017) · Acta Medica Philippina · doi:10.47895/amp.v51i2.595
Ubidecarenone (ubiquinone)
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00056-1
Parkinson's disease
(2011) · Elsevier eBooks · doi:10.1016/b978-0-7295-3908-1.10031-4
Faculty Opinions recommendation of Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
Fasano, A. A., & Breen, D. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.731430741.793539162
The Neuroprotective Role of Micronutrients in Parkinson’s Disease
Tsika, E., Ischiropoulos, H., & Malkus, K. A. (2009) · Oxidative stress and disease · doi:10.1201/9781420073522.ch2

Authors: Storch, A.
Affiliations: Technische Universität Dresden (DE)
Corresponding author: Storch, Alexander
ORCID: Storch, Alexander
Venue: Archives of Neurology
Publisher: American Medical Association (AMA)
Published: 2007-07-01
Volume: 64
Issue: 7
Pages: 938
ISSN: 0003-9942 (ISSN-L)
DOI: 10.1001/archneur.64.7.nct60005
OpenAlex: W2144592798
Cited by: 205
References: 29
Citations by year: 2026: 3 · 2025: 8 · 2024: 8 · 2023: 5 · 2022: 7 · 2021: 5 · 2020: 8 · 2019: 5 · 2018: 7 · 2017: 9 · 2016: 7 · 2015: 8 · 2014: 14 · 2013: 16 · 2012: 21
FWCI: 8.30
Type: journal article
Language: en
Open access: closed
Locations: Archives of Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords: coenzyme Q10, Parkinson's disease, levodopa, dopaminergic neurons, oxidative stress, mitochondrial bioenergetics, antioxidants, adjunctive therapy, drug safety and tolerability, Unified Parkinson's Disease Rating Scale
MeSH terms: Adult, Aged, Antioxidants, Coenzymes, Dopamine, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Energy Metabolism, Female, Humans, Levodopa, Male, Middle Aged, Neurons, Parkinson Disease, Placebos, Substantia Nigra, Ubiquinone, Vitamins, Treatment Outcome, Oxidative Stress, Cell Respiration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Randomized, Double-blind, Placebo-Controlled Trial on Symptomatic Effects of Coenzyme Q10 in Parkinson Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks